pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders.

DNA 52

DNA Immune Response Genome Genomics 52

The Pharma Data

AUGUST 24, 2020

They say genome sequencing shows the two strains of the virus are “clearly different”, making it the world’s first proven case of reinfection. Those infected develop an immune response as their bodies fight off the virus which helps to protect them against it returning. Getty Images.

Immune Response 52

Immune Response Genome Project Genome Genomics 52

pharmaphorum

NOVEMBER 28, 2021

BioNTech said in a statement that it is waiting on more data from lab tests, due in the next couple of weeks, to see if Omicron could be an “escape variant” – a strain of SARS-CoV-2 that could evade the immune responses stimulated by current vaccines.

Vaccine 111

Vaccine Vaccination Protein Genetics 111

The Pharma Data

DECEMBER 30, 2020

The Phase I/II study results, together with recently generated preclinical data, indicate that ARCT-021 leads to a potent immune response to SARS-CoV-2, and demonstrates a differentiated biological profile whereby the immune response increases in the weeks following vaccination, the company said.

Genome 52

Genome Genomics Immune Response Vaccination 52

Worldwide Clinical Trials

JUNE 15, 2022

There have been a few cases lately where patients receiving gene therapy had a severe adverse effect because of their immune response to the mechanism of the AAV viral vector, based on their own genomic markers.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

XTalks

NOVEMBER 30, 2023

These dual gRNAs target three specific sites within the HIV genome, facilitating the removal of substantial portions of the viral DNA and minimizing the potential for viral escape. The noteworthy candidate, EBT-101, is designed to eliminate HIV proviral DNA using CRISPR-Cas9 along with two guide RNAs (gRNAs).

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression.

Gene 99

Gene Immune Response Manufacturing Gene Therapy 99

The Pharma Data

JANUARY 12, 2021

“The T-cell and NK-cell target discovery approach complements our portfolio aimed at turning cold tumors hot and redirecting the innate immune system to elicit a sustained and durable immune response against tumors. For more information, please visit the company’s website at www.ksqtx.com and follow @ksq_tx on Twitter.

Development 52

Development Research In-Vivo Genome 52

The Pharma Data

APRIL 8, 2021

The Company will share a Spotlight Theater Presentation: The Orchestrated Immune Response: Dynamic Forces Guiding Cancer Immunity , introducing a novel framework for understanding the role of the immune system in cancer, with the potential to reshape the way scientists develop medicines to counteract tumour growth.

DNA 52

DNA Medicine Genome Genomics 52

The Pharma Data

DECEMBER 29, 2020

Experts believe brain-related effects may be tied to the body’s immune response to the virus and possibly to vascular problems or surges of inflammation caused by the disease. Colin Smith at Duke University Medical Center in Durham, N.C., told the Times. Most patients have been in their 30s, 40s and 50s.

Genome 52

Genome Genomics Immune Response Doctor 52

The Pharma Data

DECEMBER 31, 2020

“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.

Antibody 52

Antibody Research Bacteria Genetics 52

pharmaphorum

SEPTEMBER 4, 2020

The treatments are developed using cutting- edge technologies such as genomic sequencing and genetic engineering, helping to account for the individual variability in both patient and disease characteristics. This has gained a lot of attention in recent years due to revolutionary breakthroughs in debilitating chronic diseases such as cancer.

Medicine 58

Medicine Production Genetic Engineering Genetics 58

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome’s diagnostic searches for direct indication of tumors and signs of the immune system’s response, integrating genomics, transcriptomics, methylomics, and proteomics technologies.

Vaccine 53

Vaccine Vaccination Research Trials 53

pharmaphorum

SEPTEMBER 22, 2022

The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

JANUARY 11, 2021

Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. The team obtained sequences from the newly circulating B.1.1.7 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

The Pharma Data

APRIL 11, 2021

The scientific rationale for using immunotherapy in the neoadjuvant setting is twofold: it presents the earliest opportunity to treat cancer cells that have spread in the body without detection, and the presence of a tumor during immunotherapy treatment may enable a stronger immune response, potentially making the treatment more effective.

Trials 52

Trials Immune Response Genome Genomics 52

The Pharma Data

JUNE 19, 2022

Known as “the guardian of the genome,” p53 is a class of proteins tasked with suppressing tumor development. He said that therapies that can increase natural killer cell infiltration and/or activation in tumors are urgently needed. They conducted their first experiment with cultured mouse melanoma cells.

Drugs 52

Drugs Protein Immune Response Scientist 52

The Pharma Data

MARCH 26, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

HR 52

HR Protein Genome Genomics 52

The Pharma Data

JUNE 30, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Genome Genomics Containment 52

The Pharma Data

MAY 4, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

Protein 52

Protein HR In-Vitro Medicine 52

Cloudbyz

JULY 31, 2024

This includes tracking the persistence and function of modified cells, detecting any adverse immune responses, and ensuring that the therapeutic effects are sustained over time. Post-Treatment Monitoring: After treatment, diagnostics play a vital role in monitoring patients for potential side effects and long-term efficacy.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

XTalks

DECEMBER 17, 2021

Developing a highly effective vaccine against malaria has been technically challenging because malaria has a large and complex genome, and it’s why it’s generally more difficult to develop a vaccine against parasites than smaller viruses and bacteria. Young children are most affected by the deadly disease in the continent of Africa.

Life Science 98

Life Science Vaccination Vaccine Trials 98

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. Variants of B.1.1.7, 1.351 and P.1 2,3 Another variant, B.1.351, 4 Variant P.1,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccine 52

Roots Analysis

OCTOBER 30, 2023

Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest. This allows generation of multiple copies of the gene of interest at the target owing to the amplification property of the template.

RNA 40

RNA Vaccination Vaccine Development 40

The Pharma Data

JANUARY 4, 2021

Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. Chimeric PD-1-expressing T-cells engage with the PD-1 ligands on the surface of the cancer cells and this interaction activates the T-cells to directly kill the tumor cells. About Longwood University. About Kiromic.

In-Vivo 40

In-Vivo Development Immune Response Big Data 40

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccination 52

Vaccination Vaccine In-Vivo Genetics 52

Delveinsight

DECEMBER 13, 2020

HBV DNA can be integrated into the host genome. Hence, the persistence of cccDNA, the presence of integrated HBV DNA, and impaired innate and adaptive immune responses make it difficult to eliminate HBV from chronically infected patients. There are additional barriers to eliminating HBV.

Genotype 52

Genotype FDA Approval DNA Drugs 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Vaccination 40

Vaccination Vaccine Development Medicine 40

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Genome Genomics 52

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. This is reminiscent of influenza, another respiratory disease that requires repeated vaccinations due to its genomic instability resulting in modifications of the surface protein hemagglutinin.

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

The Pharma Data

OCTOBER 14, 2020

Additionally, immunogenicity, duration of immune response and occurrence of symptomatic COVID-19 will be measured. The study’s primary objective is to examine the safety and reactogenicity of two-doses of the vaccine. Cohort 2 (n = 10): Prime (Day 1) + Boost (Day 22) at 1 × 10 11 VP per dose.

Antibody 40

Antibody Vaccination Vaccine Trials 40

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52